• Search
  • Advanced Search

Previous issues

  • HOME
  • BROWSE ARTICLES
  • Previous issue
Volume 31(2); Apr 2025
Reviews
2092
Stem cell exosomes: new hope and future potential for relieving liver fibrosis
Lihua Li, Yongjie Liu, Kunpeng Wang, Jinggang Mo, Zhiyong Weng, Hao Jiang, Chong Jin
Clin Mol Hepatol. 2025;31(2):333-349.   Published online November 7, 2024
2117
Gut microbiota-mediated gut-liver axis: a breakthrough point for understanding and treating liver cancer
Chenyang Li, Chujun Cai, Chendong Wang, Xiaoping Chen, Bixiang Zhang, Zhao Huang
Clin Mol Hepatol. 2025;31(2):350-381.   Published online December 11, 2024
Original Articles
2109
Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023
Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed
Clin Mol Hepatol. 2025;31(2):382-393.   Published online November 29, 2024
2112
Cost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling study
Meiyu Wu, Jing Ma, Xuehong Wang, Sini Li, Chongqing Tan, Ouyang Xie, Andong Li, Aaron G Lim, Xiaomin Wan
Clin Mol Hepatol. 2025;31(2):394-408.   Published online December 3, 2024
2113
GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in metabolic dysfunction-associated steatohepatitis livers
Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Xiao-Chen Ma, Chen-He Yi, Bao-Rui Tao, Bo Zhang, Yue Ma, Guo Zhang, Rui Zhang, Yan Geng, Jing Lin, Jin-Hong Chen
Clin Mol Hepatol. 2025;31(2):409-425.   Published online December 10, 2024
2114
Integrated molecular characterization of sarcomatoid hepatocellular carcinoma
Rong-Qi Sun, Yu-Hang Ye, Ye Xu, Bo Wang, Si-Yuan Pan, Ning Li, Long Chen, Jing-Yue Pan, Zhi-Qiang Hu, Jia Fan, Zheng-Jun Zhou, Jian Zhou, Cheng-Li Song, Shao-Lai Zhou
Clin Mol Hepatol. 2025;31(2):426-444.   Published online December 10, 2024
2122
Downregulation of the MARC1 p.A165 risk allele reduces hepatocyte lipid content by increasing beta-oxidation
Ester Ciociola, Tanmoy Dutta, Kavitha Sasidharan, Lohitesh Kovooru, Francesca R. Noto, Grazia Pennisi, Salvatore Petta, Angela Mirarchi, Samantha Maurotti, Bernardette Scopacasa, Luca Tirinato, Patrizio Candeloro, Marcus Henricsson, Daniel Lindén, Oveis Jamialahmadi, Arturo Pujia, Rosellina M. Mancina, Stefano Romeo
Clin Mol Hepatol. 2025;31(2):445-459.   Published online December 23, 2024
2127
Longitudinal profile of plasma pregenomic RNA in patients with chronic hepatitis B infection on long-term nucleoside analogues and its interaction with clinical parameters
Lung-Yi Mak, Mark Anderson, Michael Stec, Matthew Shing-Hin Chung, Danny Ka-Ho Wong, Rex Wan-Hin Hui, Wai-Kay Seto, Gavin Cloherty, Man-Fung Yuen
Clin Mol Hepatol. 2025;31(2):460-473.   Published online December 26, 2024
2130
Prediction of primary biliary cholangitis among health check-up population with anti-mitochondrial M2 antibody positive
Haolong Li, Song Liu, Xu Wang, Xinxin Feng, Siyu Wang, Yanli Zhang, Fengchun Zhang, Li Wang, Tengda Xu, Yongzhe Li
Clin Mol Hepatol. 2025;31(2):474-488.   Published online December 30, 2024
2132
Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma
Weifeng Zeng, Furong Liu, Yachong Liu, Ze Zhang, Haofan Hu, Shangwu Ning, Hongwei Zhang, Xiaoping Chen, Zhibin Liao, Zhanguo Zhang
Clin Mol Hepatol. 2025;31(2):489-508.   Published online December 30, 2024
2134
Male preference for TERT alterations and HBV integration in young-age HBV-related HCC: implications for sex disparity
Jin Seoub Kim, Hye Seon Kim, Kwon Yong Tak, Ji Won Han, Heechul Nam, Pil Soo Sung, Sung Won Lee, Jung Hyun Kwon, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Jeong Won Jang
Clin Mol Hepatol. 2025;31(2):509-524.   Published online January 2, 2025
2140
Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000–2021
Pojsakorn Danpanichkul, Luis Antonio Díaz, Kanokphong Suparan, Primrose Tothanarungroj, Supapitch Sirimangklanurak, Thanida Auttapracha, Hanna L. Blaney, Banthoon Sukphutanan, Yanfang Pang, Siwanart Kongarin, Francisco Idalsoaga, Eduardo Fuentes-López, Lorenzo Leggio, Mazen Noureddin, Trenton M. White, Alexandre Louvet, Philippe Mathurin, Rohit Loomba, Patrick S. Kamath, Jürgen Rehm, Jeffrey V. Lazarus, Karn Wijarnpreecha, Juan Pablo Arab
Clin Mol Hepatol. 2025;31(2):525-547.   Published online January 9, 2025
2141
Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C
Tom Ryu, Young Chang, Soung Won Jeong, Jeong-Ju Yoo, Sae Hwan Lee, Sang Gyune Kim, Young Seok Kim, Hong Soo Kim, Seung Up Kim, Jae Young Jang
Clin Mol Hepatol. 2025;31(2):548-562.   Published online January 9, 2025
2144
Exploring methylation signatures for high de novo recurrence risk in hepatocellular carcinoma
Da-Won Kim, Jin Hyun Park, Suk Kyun Hong, Min-Hyeok Jung, Ji-One Pyeon, Jin-Young Lee, Kyung-Suk Suh, Nam-Joon Yi, YoungRok Choi, Kwang-Woong Lee, Young-Joon Kim
Clin Mol Hepatol. 2025;31(2):563-576.   Published online January 13, 2025
Editorials
2013
From invasive to intuitive: The emerging role of non-invasive models in hepatic decompensation: Editorial on “Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)”
Akhil Deshmukh, Rakhi Maiwall
Clin Mol Hepatol. 2025;31(2):577-580.   Published online August 19, 2024
Challenges and innovations in primary sclerosing cholangitis clinical trials: Evaluating HK-660S and the path forward: Editorial on “Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial”
Nilanga Nishad
Clin Mol Hepatol. 2025;31(2):581-583.   Published online November 4, 2024
A novel clinical trial for primary sclerosing cholangitis from Asia: All regional endeavors should improve global management of primary sclerosing cholangitis: Editorial on “Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial”
Atsumasa Komori
Clin Mol Hepatol. 2025;31(2):584-588.   Published online November 6, 2024
Intrapatient variability of tacrolimus trough level may be not the cause, but an indirect parameter of comorbidities: Editorial on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”
Jongman Kim
Clin Mol Hepatol. 2025;31(2):589-591.   Published online January 24, 2025
2090
Stabilizing hepatic fatty acid oxidation: Editorial on “USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination”
Myeung Gi Choi, Na Young Lee, Ja Hyun Koo
Clin Mol Hepatol. 2025;31(2):592-595.   Published online November 6, 2024
Universal self-testing as a cost-effective weapon to eliminate hepatitis C virus in the Republic of Korea: Editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiveness”
Eun Sun Jang
Clin Mol Hepatol. 2025;31(2):596-598.   Published online November 11, 2024
2126
Circulating cell-free mitochondrial DNA for diagnosing hepatocellular carcinoma and assessing prognosis: Editorial on “Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma”
Hyuk soo Eun
Clin Mol Hepatol. 2025;31(2):599-602.   Published online December 26, 2024
Momentum towards simplifying and expanding treatment for chronic hepatitis B: The body of evidence continues to grow: Editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial”
Robert J. Wong
Clin Mol Hepatol. 2025;31(2):603-605.   Published online October 29, 2024
Reconsidering treatment indications for chronic hepatitis B: Insights from the TORCH-B roll-over study: Editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial”
Chih-Wen Wang, Ming-Lung Yu
Clin Mol Hepatol. 2025;31(2):606-609.   Published online December 3, 2024
A leap in the dark: Bariatric surgery for treatment of metabolic dysfunction-associated steatotic liver disease related cirrhosis: Editorial on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
Jing Zeng, Jian-Gao Fan
Clin Mol Hepatol. 2025;31(2):610-614.   Published online December 17, 2024
2136
Treating systemic inflammation by transjugular intrahepatic portosystemic shunt: Editorial on “Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis”
Georg Semmler, Lorenz Balcar, Mattias Mandorfer
Clin Mol Hepatol. 2025;31(2):615-619.   Published online January 6, 2025
2125
Vibration-controlled transient elastography in shaping the epidemiology and management of steatotic liver disease: Editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023”
Xiao-Dong Zhou, Terry Cheuk-Fung Yip, Daniel Q Huang, Mark Dhinesh Muthiah, Mazen Noureddin, Ming-Hua Zheng
Clin Mol Hepatol. 2025;31(2):620-624.   Published online December 26, 2024
Revealing the importance of a multidisciplinary approach to reducing the global burden of SLD through the COVID-19 pandemic: Editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023”
Jeayeon Park, Su Jong Yu
Clin Mol Hepatol. 2025;31(2):625-627.   Published online January 16, 2025
Unraveling the role of GOLM1-OPN-ABCG5 axis in MASH: Editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
Yoon-su Ha, Won Kim, Seung-Jin Kim
Clin Mol Hepatol. 2025;31(2):628-630.   Published online January 16, 2025
2157
Bridging the gap: The GOLM1-OPN-ABCG5 axis in MASH and gallstone disease: Editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
Nahee Hwang, Sungsoon Fang
Clin Mol Hepatol. 2025;31(2):631-634.   Published online February 3, 2025
Genetic insights into sarcomatoid hepatocellular carcinoma: Critical role of ARID2 in pathogenesis and immune feature: Editorial on “Integrated molecular characterization of sarcomatoid hepatocellular carcinoma”
Naoshi Nishida
Clin Mol Hepatol. 2025;31(2):635-639.   Published online January 24, 2025
Is AMA M2 a useful serologic test for screening high-risk patients for PBC?: Editorial on “Prediction of primary biliary cholangitis among health check-up population with anti-mitochondrial M2 antibody positive”
Nae-Yun Heo
Clin Mol Hepatol. 2025;31(2):640-641.   Published online February 13, 2025
2146
Targeting TM4SF1 to overcome immunotherapy resistance in hepatocellular carcinoma: Editorial on “Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma”
Valerie Chew
Clin Mol Hepatol. 2025;31(2):642-645.   Published online January 16, 2025
TM4SF1 - A new immune target for treatment of hepatocellular carcinoma: Editorial on “Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma”
Chen Rui Yuan, Terence Kin Wah Lee
Clin Mol Hepatol. 2025;31(2):646-649.   Published online February 10, 2025
2174
Tetraspan(in)-mediated immune regulation in hepatocellular carcinoma: Editorial on “Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma”
Seo Hee Jin, Dong Joo Kim, Jung Weon Lee
Clin Mol Hepatol. 2025;31(2):650-653.   Published online February 11, 2025
Burden of alcohol use disorder, alcohol-related liver disease, and alcohol-related liver cancer: Editorial on “Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000–2021
Youxin Wang, Noriko Oza, Jazleen Leo, Ashok Choudhury, Daniel Q. Huang
Clin Mol Hepatol. 2025;31(2):654-657.   Published online February 10, 2025
Metabolic dysfunction in patients following DAA-induced viral cure for HCV infection: A non-negligible risk to liver-related health: Editorial on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”
Chen-Hua Liu, Yu-Ping Chang
Clin Mol Hepatol. 2025;31(2):658-661.   Published online February 17, 2025
Screening of patients at high risk of de novo recurrence in HCC: Editorial on “Exploring methylation signatures for high de novo recurrence risk in hepatocellular carcinoma”
Ping Huang, Shiqiao Luo, Rui Liao
Clin Mol Hepatol. 2025;31(2):662-664.   Published online February 11, 2025
Snapshot
2072
Modulation of lymphatic vessels in management of liver disease and complications
Aarti Sharma, Pinky Juneja, Shiv K Sarin, Savneet Kaur
Clin Mol Hepatol. 2025;31(2):665-668.   Published online October 17, 2024
Erratum
Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial’ [Clin Mol Hepatol 2024;30:807-823]
Sun Young Yim, Sung Hwan Lee, Seung-Woo Baek, Bohwa Sohn, Yun Seong Jeong, Sang-Hee Kang, Kena Park, Hyewon Park, Sunyoung S. Lee, Ahmed O. Kaseb, Young Nyun Park, Sun-Hee Leem, Michael A. Curran, Ji Hoon Kim, Ju-Seog Lee
Clin Mol Hepatol. 2025;31(2):669-670.   Published online February 27, 2025
Letters to the Editor
Letter to the editor on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
Hai Xu, Yong Zhou, Huikun Wu
Clin Mol Hepatol. 2025;31(2):e125-e127.   Published online December 17, 2024
MAFLD or MASLD: Which better represents the prognosis of the steatotic liver population: Letter to the editor on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
Ying Wang, Shengfeng Wang, Xiude Fan, Jiajun Zhao, Yongfeng Song
Clin Mol Hepatol. 2025;31(2):e128-e133.   Published online December 26, 2024
Global inequality in the burden of hepatitis B from 1990 to 2021: Findings from the global burden of disease study 2021: Letter to the editor on “Comprehensive approach to controlling chronic hepatitis B in China”
Chunlong Liu, Jiangtao Yu
Clin Mol Hepatol. 2025;31(2):e134-e136.   Published online December 17, 2024
Tacrolimus levels and variability in CKD and ESRD risk post-liver transplant: Letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”
Rui Shi, Minghua Wang
Clin Mol Hepatol. 2025;31(2):e137-e139.   Published online January 9, 2025
Treatment response to nucleos(t)ide analogs in chronic hepatitis B with mildly elevated alanine aminotransferase: Letter to the editor on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial”
Jian Wang, Fei Cao, Chuanwu Zhu, Chao Wu, Rui Huang
Clin Mol Hepatol. 2025;31(2):e140-e142.   Published online December 3, 2024
Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
Wei Wang, Yating Xie, Ailei Xu
Clin Mol Hepatol. 2025;31(2):e143-e144.   Published online February 18, 2025
Prevalence of steatotic liver disease and associated fibrosis in the general population: An epidemiological survey: Letter to the editor on “Epidemiology of metabolic dysfunction-associated steatotic liver disease”
Lin Guan, Xinhe Zhang, Shanghao Liu, Xiaolong Qi, Yiling Li
Clin Mol Hepatol. 2025;31(2):e145-e148.   Published online October 29, 2024
Correspondences
Correspondence to letter to the editor on “Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults”
Chang Hun Lee, In Hee Kim, Sook-Hyang Jeong
Clin Mol Hepatol. 2025;31(2):e149-e151.   Published online November 6, 2024
Age serves as the silent architect of FIB-4’s precision in unveiling advanced hepatic fibrosis in MASLD with T2DM: Correspondence to letter to the editor on “Diagnostic accuracy of the fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liver disease with type 2 diabetes: a systematic review and meta-analysis”
Ji Won Han, Dae Won Jun
Clin Mol Hepatol. 2025;31(2):e152-e154.   Published online December 30, 2024
Correspondence to editorial on “Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)”
Chuan Liu, Ling Yang, Hong You, Gao-Jun Teng, Xiaolong Qi
Clin Mol Hepatol. 2025;31(2):e155-e157.   Published online August 30, 2024
Correspondence to editorial on “Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial”
Woo Hyun Paik, Do Hyun Park
Clin Mol Hepatol. 2025;31(2):e158-e160.   Published online November 11, 2024
Correspondence to editorial on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”
Soon Kyu Lee, Jong Young Choi
Clin Mol Hepatol. 2025;31(2):e161-e162.   Published online February 13, 2025
HCV self-testing: Bridging screening gaps and ensuring cost-effectiveness for both high-risk and universal populations: Correspondence to editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiveness”
Gyeongseon Shin, Beom Kyung Kim, SeungJin Bae, Hankil Lee, Sang Hoon Ahn
Clin Mol Hepatol. 2025;31(2):e163-e165.   Published online November 29, 2024
Correspondence to editorial on “Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma”
Yang Liu, Fan Peng, Siyuan Wang, Jinliang Xing
Clin Mol Hepatol. 2025;31(2):e166-e168.   Published online January 6, 2025
Expanding treatment eligibility for chronic hepatitis B: Balancing benefits, limitations, and healthcare access: Correspondence to editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial”
Yao-Chun Hsu, Chi-Yi Chen, Jaw-Town Lin
Clin Mol Hepatol. 2025;31(2):e169-e172.   Published online December 23, 2024
Correspondence to editorial on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
Nicholas A. Rouillard, Linda Henry, Mindie H. Nguyen
Clin Mol Hepatol. 2025;31(2):e173-e175.   Published online January 9, 2025
TIPS insertion and systemic inflammation: Is it ever too late to lower portal pressure? Correspondence to editorial on “Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis”
Anja Tiede, Benjamin Maasoumy
Clin Mol Hepatol. 2025;31(2):e176-e179.   Published online February 10, 2025
Addressing the burden of steatotic liver disease: The role of transient elastography: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”
Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed
Clin Mol Hepatol. 2025;31(2):e180-e182.   Published online February 13, 2025
The burden of steatotic liver disease before and during the COVID-19 pandemic: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”
Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed
Clin Mol Hepatol. 2025;31(2):e183-e185.   Published online February 17, 2025
Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Jing Lin, Jin-Hong Chen
Clin Mol Hepatol. 2025;31(2):e186-e188.   Published online January 24, 2025
GOLM1 and bile acid synthesis: Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Jing Lin, Jin-Hong Chen
Clin Mol Hepatol. 2025;31(2):e189-e191.   Published online February 13, 2025
Correspondence to editorial on “Integrated molecular characterization of sarcomatoid hepatocellular carcinoma”
Rong-Qi Sun, Shao-Lai Zhou
Clin Mol Hepatol. 2025;31(2):e192-e193.   Published online February 26, 2025
Correspondence to editorial on “Prediction of primary biliary cholangitis among health check-up population with anti-mitochondrial M2 antibody positive”
Haolong Li, Song Liu, Xu Wang, Li Wang, Tengda Xu, Yongzhe Li
Clin Mol Hepatol. 2025;31(2):e194-e196.   Published online February 24, 2025
Correspondence to editorial on “Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma”
Weifeng Zeng, Furong Liu, Yachong Liu, Zhanguo Zhang
Clin Mol Hepatol. 2025;31(2):e197-e199.   Published online February 5, 2025
Correspondence to editorial on “Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000-2021”
Pojsakorn Danpanichkul, Luis Antonio Diaz, Kanokphong Suparan, Karn Wijarnpreecha, Juan Pablo Arab
Clin Mol Hepatol. 2025;31(2):e200-e202.   Published online February 17, 2025
Correspondence to editorial on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”
Tom Ryu, Young Chang, Seung Up Kim, Jae Young Jang
Clin Mol Hepatol. 2025;31(2):e203-e205.   Published online February 24, 2025
Correspondence to editorial on “Exploring methylation signatures for high de novo recurrence risk in hepatocellular carcinoma”
Kwang-Woong Lee, Young-Joon Kim
Clin Mol Hepatol. 2025;31(2):e206-e207.   Published online February 17, 2025
Correspondence to letter to the editor 1 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
Seogsong Jeong, Won Kim, Sang Min Park
Clin Mol Hepatol. 2025;31(2):e208-e209.   Published online January 6, 2025
Correspondence to letter to the editor 2 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
Seogsong Jeong, Won Kim, Sang Min Park
Clin Mol Hepatol. 2025;31(2):e210-e211.   Published online January 6, 2025
Correspondence to letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”
Soon Kyu Lee, Jong Young Choi
Clin Mol Hepatol. 2025;31(2):e212-e214.   Published online February 10, 2025
Replys to Correspondence
Reply to correspondence on “Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma”
Hyuk Soo Eun
Clin Mol Hepatol. 2025;31(2):e215-e217.   Published online January 16, 2025
Reply to correspondence on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
Jing Zeng, Jian-Gao Fan
Clin Mol Hepatol. 2025;31(2):e218-e220.   Published online February 3, 2025
Reply to correspondence on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”
Jeayeon Park, Su Jong Yu
Clin Mol Hepatol. 2025;31(2):e221-e223.   Published online March 4, 2025
Decreasing systemic inflammation after TIPS: Still hope for the liver: Reply to correspondence on “Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis”
Georg Semmler, Lorenz Balcar, Mattias Mandorfer
Clin Mol Hepatol. 2025;31(2):e224-e225.   Published online February 17, 2025
Reply to correspondence 1 on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
Yoon-su Ha, Won Kim, Seung-Jin Kim
Clin Mol Hepatol. 2025;31(2):e226-e227.   Published online February 13, 2025
Reply to correspondence 2 on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
Nahee Hwang, Sungsoon Fang
Clin Mol Hepatol. 2025;31(2):e228-e231.   Published online February 26, 2025
Reply to correspondence on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”
Chen-Hua Liu, Yu-Ping Chang
Clin Mol Hepatol. 2025;31(2):e232-e233.   Published online February 26, 2025

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: cmh_journal@ijpnc.com
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 661
TOTAL : 2631660
Close layer